Sunday, February 15, 2026 2/15/2026

Translational Gene Therapy for CNGB1 Retinitis Pigmentosa

Award Number: R24EY027285
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2018
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

Translational Gene Therapy for CNGB1 Retinitis Pigmentosa - Currently there is no treatment for autosomal recessive retinitis pigmentosa (arRP) due to mutations in rod photoreceptor genes. This multi-investigator, multi-center research project will fill this gap by optimizing recombinant adeno-associated virus (rAAV) vector gene augmentation therapy for cyclic nucleotide-gated channel beta 1 (CNGB1) linked RP. The optimized vector will be taken through the stages needed for an investigational new drug (IND) submission in preparation for a future phase I/II clinical trial. The collaborative team has expertise in rAAV vector development and production, preclinical and clinical trials for retinal dystrophies, clinical assessment and recruitment of arRP patients, CNG channel physiology and small and large animal proof-of-concept gene therapy studies. There are compelling reasons to select CNGB1-RP to fill this unmet need. First, CNGB1 mutations cause a loss of rod function, but only a slow loss of rods, meaning there is a wide window of opportunity for intervention while there are still remaining rods. Second, there are well characterized small (mouse) and large (dog) animal models of CNGB1-RP that recapitulate the human phenotype. Third, in both CNGB1-RP models rAAV gene augmentation therapy can efficiently (1) rescue the function and (2) delay the degeneration of rods. There are four aims to the project: Aim 1 is development of an optimized vector that efficiently and specifically targets rod photoreceptors in nonhuman primates. We will start with an efficient vector with a new short rhodopsin promoter that has already shown efficacy in CNGB1-RP animal models. The final rAAV-CNGB1 vector will be used to start the Good Manufacturing Practice (GMP) process development. This final vector will be used to investigate duration of rescue achievable in mouse and dog CNGB1-RP models and also answer the important question of how late in the process of rod degeneration can rescue and preservation of structure be obtained?” Aim 2 will consist of recruitment of candidate patients for the clinical trial. A barrage of clinical testing methods will be used over a three year period to precisely describe the RP phenotype and identify optimal outcome measures for a future clinical trial. The testing will also ascertain if there is similar disease progression between the two eyes which would allow the second eye to be used as a non treatment control. Aim 3 will consist of the animal toxicology and pharmacokinetic and efficacy studies needed for IND submission. We propose a standard GLP toxicology/biodistribution study in rats coupled with a hybrid efficacy/safety study using the CNGB1-RP dog model. A pre-IND meeting with the FDA will review the study design and ensure that it meets regulatory requirements. GMP vector production will then be completed. Finally, in Aim 4 we will prepare and submit an IND application. This project fulfills the FOA goal of “development of a therapeutic, which can then be tested in a clinical trial.”


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Vision Research	000	5	3/7/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Vision Research	000	5	2/26/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $1,517,749 )
2022	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Vision Research	001	5	3/9/2022	NON-COMPETING CONTINUATION	$1,517,749
2022	2022	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Vision Research	002	5	8/22/2022	NON-COMPETING CONTINUATION	$0
2022	2021	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Vision Research	000	4	1/14/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,517,749

Issue Date FY: 2021 ( Subtotal = $2,191,579 )
2021	2021	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Vision Research	000	4	3/8/2021	NON-COMPETING CONTINUATION	$1,828,029
2021	2021	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Vision Research	001	4	9/7/2021	SUPPLEMENT FOR EXPANSION	$363,550
														Subtotal = $2,191,579

Issue Date FY: 2020 ( Subtotal = $1,832,126 )
2020	2020	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Vision Research	000	3	4/15/2020	NON-COMPETING CONTINUATION	$1,832,126
														Subtotal = $1,832,126

Issue Date FY: 2019 ( Subtotal = $1,783,428 )
2019	2019	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Vision Research	000	2	2/28/2019	NON-COMPETING CONTINUATION	$1,783,428
														Subtotal = $1,783,428

Issue Date FY: 2018 ( Subtotal = $1,253,534 )
2018	2018	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Vision Research	000	1	3/26/2018	NEW	$1,253,534
														Subtotal = $1,253,534

Grand Total All Awards = $8,578,416

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Translational Gene Therapy for CNGB1 Retinitis Pigmentosa

Award Number: R24EY027285

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2018

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer